Publications2021-07-02T08:15:47-04:00

Publication Library

TRANSPLANT GENOMICS RECEIVES GEISINGER HEALTH PLAN COVERAGE FOR TRUGRAF AND VIRACOR TRAC KIDNEY TESTS

Humana’s kidney transplant patients are covered effective January 30, 2023, for non-invasive rejection testing with the TruGraf® blood gene expression test and the Viracor TRAC® (Transplant Rejection Allograft Check), donor-derived cell-free DNA test.

FRAMINGHAM, MA — Eurofins Transplant Genomics, Inc. (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is excited to announce the first commercial coverage contract for TruGraf, its proprietary gene expression test for subclinical acute rejection and Viracor TRAC, it’s donor-derived cell-free DNA test to determine active rejection. Geisinger, a leading not-for profit health care Pennsylvania corporation, offered coverage for both TruGraf and Viracor TRAC tests effective January 30, 2023.

TruGraf is the first blood gene expression test approved by CMS/Medicare. TruGraf offers early detection of “silent” subclinical acute rejection in kidney transplant patients with stable kidney function before organ injury and acute rejection begins. This novel biomarker test offers transplant patients a non-invasive option for otherwise painful biopsy procedures, leading to detection of subclinical chronic rejection, and an improved quality of life. Likewise, Viracor TRAC, approved by CMS/Medicare, offers early detection of active kidney rejection.

Geisinger will cover the TGI TruGraf and Viracor TRAC tests for their non-Medicare Products (Commercial HMO/PPO/POS and Third-Party Administrator plans), their Medicare Advantage Products and their Marketplace/Exchange Products.

Transplant Genomics is thrilled that Geisinger has extended coverage for TruGraf and Viracor TRAC making this suite of tests more easily accessible for their kidney transplant patient population. TGI is committed to working in partnership with payors to ensure as many patients as possible can benefit from our non-invasive approach to improving transplant health.

For more information:

Brian Tees

Transplant Genomics, Inc.

BrianTees@viracor.eurofinsus.com

About Transplant Genomics, Inc.

Eurofins Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family of companies, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. Our flagship product is TruGraf, the only non-invasive blood test approved by CMS that offers early detection of “silent” subclinical acute rejection in kidney transplant recipients with stable graft function. Test services are offered through TGI’s CLIA laboratory in Lenexa, Kansas. TGI was acquired by Eurofins Scientific in 2019.

Learn more about Transplant Genomics at http://www.transplantgenomics.com

About Eurofins Scientific

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins network of companies believes that it is the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Learn more about Eurofins at https://www.eurofins.com.

About Geisinger Health Plans

For the third year in a row, Geisinger Health Plan ranked best among commercial health plans in Pennsylvania for member satisfaction in the J.D. Power 2022 U.S. Commercial Member Health Plan Study. It maintains a provider network of more than 29,000 doctors and 100 hospitals across Pennsylvania. And more than half a million members trust Geisinger Health Plan for their healthcare coverage.

Learn more about Geisinger at https://www.geisinger.org/health-plan

October 2023|

Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients

Clinical Journal of the American Society of Nephrology, October 2021, https://doi.org/10.2215/CJN.05530421

Sookhyeon Park, Kexin Guo, Raymond L. Heilman, Emilio D. Poggio, David J. Taber, Christopher L. Marsh, Sunil M. Kurian, Steve Kleiboeker, Juston Weems, John Holman, Lihui Zhao, Rohita Sinha, Susan Brietigam, Christabel Rebello, Michael M. Abecassis and John J. Friedewald.

October 2021|

Discovery and Validation of a Novel Blood‐Based Molecular Biomarker of Rejection following Liver Transplantation

American Journal of Transplantation 30 April 2020 https://doi.org/10.1111/ajt.15953

Josh Levitsky, Sumeet K. Asrani,  Thomas Schiano, Adyr Moss, Kenneth Chavin, Charles Miller, Kexin Guo, Lihui Zhao, Manoj Kandpal, Nancy Bridges, Merideth Brown, Brian Armstrong, Sunil Kurian, Anthony J. Demetris, Michael Abecassis, The Clinical Trials in Organ Transplantation – 14 Consortium
May 2020|
Go to Top